-
Antidromic strategies to target RASopathies
Antidromic strategies to target RASopathies
- RAS detected at low levels on cell surface independent of the HLA complex
- Targeting of extracellularly expressed RAS on cancer cells via bispecific T cell engager
- Relevant for novel immunotherapies for RAS-driven malignancies
-
NF-κB-activated dendritic cells
NF-κB-activated dendritic cells
- that has very little adverse effects and overcomes the limitations of DC based immunotherapy approaches
- DCs activation is mediated by via mRNA transfection
- Activated DCs lead to strong expansion of memory T cells and are much more stable than other DC vaccination products
2 of 96 Tech Offers
